Which has preferable earnings and valuation, IMVT or BIIB?

Biogen has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Biogen $9.89B 3.35 $1.29B $5.65 39.74

Is IMVT or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Immunovant's net margin of 0.00%. Biogen's return on equity of 11.18% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Biogen 8.32% 11.18% 6.88%

Does the media refer more to IMVT or BIIB?

In the previous week, Biogen had 35 more articles in the media than Immunovant. MarketBeat recorded 40 mentions for Biogen and 5 mentions for Immunovant. Biogen's average media sentiment score of 1.22 beat Immunovant's score of 0.98 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 29 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or IMVT?

In the previous week, Alnylam Pharmaceuticals had 20 more articles in the media than Immunovant. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 5 mentions for Immunovant. Immunovant's average media sentiment score of 0.98 beat Alnylam Pharmaceuticals' score of 0.90 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BNTX or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Immunovant N/A -69.59% -62.49%

Does the media prefer BNTX or IMVT?

In the previous week, BioNTech had 12 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for BioNTech and 5 mentions for Immunovant. Immunovant's average media sentiment score of 0.98 beat BioNTech's score of -0.18 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INSM or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Immunovant's return on equity of -69.59% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Immunovant N/A -69.59% -62.49%

Does the media prefer INSM or IMVT?

In the previous week, Insmed had 4 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Insmed and 5 mentions for Immunovant. Immunovant's average media sentiment score of 0.98 beat Insmed's score of 0.89 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMVT or ROIV?

In the previous week, Roivant Sciences had 13 more articles in the media than Immunovant. MarketBeat recorded 18 mentions for Roivant Sciences and 5 mentions for Immunovant. Immunovant's average media sentiment score of 0.98 beat Roivant Sciences' score of 0.80 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 9 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunovant (IMVT) Competitors

$39.12 -0.37 (-0.94%)

As of 04:00 PM Eastern

Compare

IMVT vs. BIIB, ALNY, BNTX, INSM, and ROIV

Should you buy Immunovant stock or one of its competitors? Immunovant's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioNTech (BNTX), Insmed (INSM), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunovant compare to Biogen?

Immunovant (NASDAQ:IMVT) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Immunovant presently has a consensus target price of $44.00, suggesting a potential upside of 12.47%. Biogen has a consensus target price of $228.50, suggesting a potential upside of 1.78%. Given Immunovant's higher probable upside, equities research analysts clearly believe Immunovant is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

47.1% of Immunovant shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 1.9% of Immunovant shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Immunovant has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

In the previous week, Biogen had 35 more articles in the media than Immunovant. MarketBeat recorded 40 mentions for Biogen and 5 mentions for Immunovant. Biogen's average media sentiment score of 1.22 beat Immunovant's score of 0.98 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	29 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a net margin of 8.32% compared to Immunovant's net margin of 0.00%. Biogen's return on equity of 11.18% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Biogen	$9.89B	3.35	$1.29B	$5.65	39.74

Summary

Biogen beats Immunovant on 13 of the 16 factors compared between the two stocks.

How does Immunovant compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

In the previous week, Alnylam Pharmaceuticals had 20 more articles in the media than Immunovant. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 5 mentions for Immunovant. Immunovant's average media sentiment score of 0.98 beat Alnylam Pharmaceuticals' score of 0.90 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	13 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Immunovant's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Immunovant	N/A	-69.59%	-62.49%

Alnylam Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	9.53	$313.75M	$5.38	49.16
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Alnylam Pharmaceuticals presently has a consensus target price of $386.14, suggesting a potential upside of 45.99%. Immunovant has a consensus target price of $44.00, suggesting a potential upside of 12.47%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Immunovant on 13 of the 16 factors compared between the two stocks.

How does Immunovant compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Immunovant has lower revenue, but higher earnings than BioNTech. Immunovant is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	8.01	-$1.29B	-$7.83	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioNTech presently has a consensus price target of $127.44, indicating a potential upside of 23.87%. Immunovant has a consensus price target of $44.00, indicating a potential upside of 12.47%. Given BioNTech's stronger consensus rating and higher possible upside, research analysts plainly believe BioNTech is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, BioNTech had 12 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for BioNTech and 5 mentions for Immunovant. Immunovant's average media sentiment score of 0.98 beat BioNTech's score of -0.18 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Immunovant	N/A	-69.59%	-62.49%

BioNTech has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Summary

BioNTech beats Immunovant on 11 of the 16 factors compared between the two stocks.

How does Immunovant compare to Insmed?

Insmed (NASDAQ:INSM) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Insmed had 4 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Insmed and 5 mentions for Immunovant. Immunovant's average media sentiment score of 0.98 beat Insmed's score of 0.89 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Immunovant's return on equity of -69.59% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Immunovant	N/A	-69.59%	-62.49%

Insmed currently has a consensus target price of $205.52, indicating a potential upside of 62.24%. Immunovant has a consensus target price of $44.00, indicating a potential upside of 12.47%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Immunovant has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$1.14B	24.32	-$1.28B	-$4.11	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

47.1% of Immunovant shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 1.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Summary

Insmed beats Immunovant on 9 of the 16 factors compared between the two stocks.

How does Immunovant compare to Roivant Sciences?

Immunovant (NASDAQ:IMVT) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Roivant Sciences had 13 more articles in the media than Immunovant. MarketBeat recorded 18 mentions for Roivant Sciences and 5 mentions for Immunovant. Immunovant's average media sentiment score of 0.98 beat Roivant Sciences' score of 0.80 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	9 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has higher revenue and earnings than Immunovant. Roivant Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Roivant Sciences	$7.53M	3,299.94	-$299.77M	-$0.53	N/A

Immunovant has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Immunovant currently has a consensus target price of $44.00, suggesting a potential upside of 12.47%. Roivant Sciences has a consensus target price of $35.14, suggesting a potential upside of 2.11%. Given Immunovant's higher possible upside, analysts plainly believe Immunovant is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Immunovant has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Summary

Roivant Sciences beats Immunovant on 12 of the 16 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMVT vs. The Competition

Export

Metric	Immunovant	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.08B	$4.02B	$7.25B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.57%
P/E Ratio	-13.87	12.72	273.59	25.45
Price / Sales	N/A	1,361.39	675.80	123.67
Price / Cash	N/A	105.29	76.98	52.10
Price / Book	10.99	16.29	12.89	6.14
Net Income	-$505.61M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-10.73%	-1.38%	-0.33%	-1.47%
1 Month Performance	1.58%	11.06%	6.51%	2.47%
1 Year Performance	134.25%	53.71%	25.19%	15.84%

Immunovant Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMVT Immunovant	1.7051 of 5 stars	$39.12 -0.9%	$44.00 +12.5%	+162.0%	$8.08B	N/A	N/A	120
BIIB Biogen	3.0795 of 5 stars	$218.12 +0.6%	$227.07 +4.1%	+59.5%	$32.03B	$9.89B	38.61	7,500	Trending News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.6008 of 5 stars	$236.01 -0.1%	$386.62 +63.8%	-40.2%	$31.61B	$3.71B	43.87	2,770	Analyst Forecast
BNTX BioNTech	3.1907 of 5 stars	$112.82 -3.2%	$127.81 +13.3%	+3.2%	$29.48B	$3.25B	N/A	7,807	Analyst Forecast
INSM Insmed	3.5248 of 5 stars	$123.98 -1.4%	$205.52 +65.8%	-12.8%	$27.47B	$1.14B	N/A	1,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMVT) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Competitors